Antisense therapy in clinical oncology: preclinical and clinical experiences.
Tamm
Ingo
I
Department of Hematology and Oncology, Charite, Campus Virchow, Humboldt University of Berlin, Germany.
D000818:Animals; D002986:Clinical Trials as Topic; D017868:Cyclic AMP-Dependent Protein Kinases / Q000235:genetics; D015254:DNA Modification Methylases / Q000235:genetics; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D007938:Leukemia / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000235:genetics; D051571:Protein Kinase C-alpha; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D020598:Proto-Oncogene Proteins c-myb / Q000235:genetics; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000235:genetics; D053781:Transforming Growth Factor beta2
D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D020598:Proto-Oncogene Proteins c-myb; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D015254:DNA Modification Methylases; D019908:Proto-Oncogene Proteins c-raf; D017868:Cyclic AMP-Dependent Protein Kinases; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha